Clinical trial
The Primary Objective of This Study is to Determine Whether MICARDIS® Improves…
NCT00146289 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00146289 |
|---|---|
| Title | The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects |
| Official title | A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Obesity, Insulin Resistance |
| Intervention type | Drug |
| Interventions | MICARDIS® (telmisartan) |
| Enrollment | 138 |
| Start date | Feb 1, 2005 |
| Primary completion | Oct 1, 2005 |
| First posted | Sep 7, 2005 |
| Last update posted | Nov 1, 2013 |
| Countries | Canada, Denmark, Germany, Italy, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: